Rheumatology

Back to articles

Safer colchicine dosing regimen approved

KEY POINT

FDA has approved colchicine (Colcrys—Mutual) tablets with a much lower dosing regimen for gout flares compared with historic dosing. The approval was accompanied by warnings for potential serious and lifethreatening drug interactions if colchicine is coadministered with P-glycoprotein (P-gp) or strong cytochrome P450 (CYP)3A4 inhibitors.

Recent Articles